TOP > 外国特許検索 > THERAPEUTIC AGENT FOR SARCOPENIA AND METABOLIC DISEASES

THERAPEUTIC AGENT FOR SARCOPENIA AND METABOLIC DISEASES

外国特許コード F170009012
整理番号 (S2015-2004-N0)
掲載日 2017年3月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP076627
国際公開番号 WO 2017043630
国際出願日 平成28年9月9日(2016.9.9)
国際公開日 平成29年3月16日(2017.3.16)
優先権データ
  • 特願2015-179698 (2015.9.11) JP
発明の名称 (英語) THERAPEUTIC AGENT FOR SARCOPENIA AND METABOLIC DISEASES
発明の概要(英語) The present invention provides a therapeutic agent for sarcopenia or metabolic diseases, which contains a mu-crystalline (CRYM)-inhibiting substance as an active ingredient. The inhibiting substance is selected from the group consisting of an antisense nucleic acid for CRYM, an RNAi-induced nucleic acid, a ribozyme or an expression vector therefore, an antagonist antibody, and a low-molecular-weight compound capable of inhibiting the activity of CRYM.
従来技術、競合技術の概要(英語) BACKGROUND ART
Is skeletal muscle, and maximal tissue in the body, accounts for 40-50% of body weight. Is skeletal muscle, a variety of physical activity in response to the stimulus, as well as muscle contraction and metabolism characteristics can be easily adapted to the size of a tissue of a highly plasticized. How the elasticity of the muscle to understand adjusted is, in the heart muscle biology and regenerative medicine is high and, muscular dystrophy, cancer cachexia and sarcopenia associated with aging such as failure of particular relevance to maintain muscle muscle disease (non-patent document 1, 2). The characteristics of the skeletal muscle, and having an anabolic or catabolic hormones and growth factors to be affected by. Thyroid hormones, normal development, cell proliferation and differentiation, heat production, controlling calcium homeostasis and physiological functions such as to have an important role in a wide range of (non-patent document 3-5). In skeletal muscle, thyroid hormone, speed muscle glycolysis plays an important role in the conversion of type (non-patent document 4,6-8).
Is mu crystallin (CRYM), was first discovered in kangaroo and lens, triiodothyronine (T3) from the cytoplasm to the nucleus of that regulate the transport NADPH dependent cytosolic triiodothyronine (T3) the characterization as binding proteins (non-patent document 9-11). Is CRYM, thyroid hormone receptor is a dimer comprising T3 to facilitate bonding and thyroid hormone action by a positive regulator, which in turn binds to its response element and the genome of the thyroid, thyroid hormone response genes in the nucleus to modulate the expression. However, mice deficient in CRYM, peripheral T3 to modify the action normally without exhibiting the growth of (non-patent document 12).
Muscular dystrophy (FSHD) is the upper shoulder face, an autosomal dominant disease, characterized by a unique pattern suffering from muscle, and particularly the facial skin and scapular band after lowering of the amount of muscle with muscle weakness of the lower extremities (non-patent document 13, 14). FSHD in muscle of the patient, an abnormally high expression has been reported CRYM while, in some other myopathies and muscular dystrophy, that are capable of up-regulation CRYM not observed (non-patent document 15). In another study, FSHD muscle myoblasts derived from highly expressed protein CRYM, CRYM FSHD DUX4 - related transcription factors directly induce expression is suggested (non-patent document 16). In addition, a method of diagnosing CRYM FSHD as a marker molecule is known (patent document 1).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGASAKI UNIVERSITY
  • 発明者(英語)
  • ONO, Yusuke
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
上記の特許・技術に関心のある方は、下記問い合わせ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close